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Malaria in Pacific Populations: Seen but not Heard?

Abstract
Most Pacific Island countries are located in the tropics, where there is an abundance of mosquitoes with the potential to carry debilitating or life-threatening vector-borne diseases. This article examines three Melanesian countries in which malaria is endemic—Papua New Guinea, Solomon Islands and Vanuatu—but the threat posed by the spread of malaria gives the issues a broader significance to the Pacific region. After discussing the spatial distribution and prevalence of malaria in the Pacific, the article examines a range of health interventions through which people have sought to control malaria. Although the disease was nearly eradicated in the Pacific in the 1970s, it is no longer in retreat. The article concludes by examining why there are still grounds for cautious optimism, and the challenges that Pacific Island countries face in reducing the impact of malaria on their populations. There is a need for prompt and concerted action on malaria at the national, regional and international levels if the public health concerns arising from the disease are to be adequately addressed.
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Since the 19th century, industrialised countries have undergone a health transition in which there has been a substantial decline in mortality and morbidity from acute infectious diseases, particularly among the young, and a rise in chronic non-communicable diseases that affect older cohorts (Omran 1971). Yet many developing countries have not enjoyed the benefits of a corresponding health transition. For them, the reality is often a ‘triple burden of disease’ arising from the ongoing issue of communicable diseases, the increasing burden of non-communicable diseases due to adoption of Western lifestyles, and emerging health threats posed by environmental and climate change (Abal 2007).
The experience of many Pacific Island countries has been similar to other less-developed and least-developed countries. This is reflected in the ‘Pacific Plan’, which was adopted by the leaders of 16 Pacific countries in 2005 as a roadmap for strengthening regional cooperation. The Plan aims to promote sustainable development, in part through improving the health of Pacific populations. Although the Plan specifically identifies the importance of controlling non-communicable diseases and one communicable disease (dengue), notably absent from the implementation strategies is any reference to malaria, which continues to have a deleterious effect on the health and well-being of some Pacific populations (PIFS 2005).
This article examines malaria in Pacific populations and considers whether enough is being done to address the public health concerns arising from the disease, or whether malaria is instead ‘seen but not heard’ by those who may have the capacity to mitigate the disease in the Pacific. The article focuses on the three Melanesian countries in which malaria is endemic—Papua New Guinea, Solomon Islands and Vanuatu—but the threat posed by the spread of malaria to other Pacific Island countries gives it broader regional relevance.
Malaria is a biologically complex disease. The article explains its life cycle and discusses the web of relationships between malaria parasites, mosquito vectors and human hosts. The article describes the distribution of malaria, globally and within the Pacific, and notes the ecological boundary that separates the malarious countries of Melanesia from the malaria-free countries to the east. Data are presented showing the incidence of malaria in recent years. This imposes significant human, social and economic costs, yet the true burden of the disease must be understood in the context of the culture, values and beliefs of traditional Melanesian societies. The article examines a range of health interventions through which people have sought to control malaria since the parasitic basis of the disease was first discovered. Although malaria was nearly eradicated in the 1960s and 1970s, it is no longer in retreat. The article concludes by examining why there are still grounds for cautious optimism, despite the challenges that Pacific Island countries face in reducing the impact of malaria on their populations.

Parasites, vectors and hosts
The word malaria derives from the Italian ‘mal aria’, meaning ‘bad air’. The name reflected the view of the Ancient Romans that the disease emanated from swamp fumes (Finkel 2007). The idea that diseases were caused by foul emanations from soil, air and water persisted long into the 19th century, reflecting the miasma theory of disease.
Only in the latter half of the 19th century did new scientific work give rise to the view that infections might be caused by minute organisms (Susser and Susser 1996). The birth of the germ theory of disease also brought with it the quest to find the pathogen responsible for malaria. The discovery of a parasite as the disease agent in 1880 is generally attributed to a French army doctor, Alphonse Laveran, who investigated the disease among the French Foreign Legion in Algeria. It took further work by an Italian zoologist, Giovanni Grassi, and an English physician, Ronald Ross, to confirm the transmission mechanism some 17 years later (Bruce-Chwatt 1981; Spielman and D’Antonio 2001).
Malaria is now known to be caused by infection of human red blood cells with protozoan parasites of the genus Plasmodium. The parasite utilises two host organisms in its complex life cycle—a mosquito vector and a vertebrate host. A female mosquito must take at least two blood meals during her lifetime to transmit the parasite. By the first meal, the vector acquires the parasite from an infective host. By the second meal, the vector transmits the parasite through her saliva into the blood of another vertebrate host. From there the parasite moves to the host’s liver, where it multiples, eventually bursting into the bloodstream. Once in the bloodstream, the parasite attacks red blood cells. The response of the vertebrate host to infection by the parasite gives rise to the disease we know as malaria. When red blood cells in the brain are involved, the infection results in the often fatal condition of cerebral malaria.
Protozoan parasites
Of the many known species of Plasmodium, only four infect humans routinely: P. falciparum, P. vivax, P. ovale, and P. malariae (Garnham 1966 (​http:​/​​/​en.wikipedia.org​/​wiki​/​1966" \o "1966​)). The most virulent of these is P. falciparum, which accounts for a very high proportion of global deaths and is predominantly found in Africa. Far more common is P. vivax, which accounts for a large proportion of global malaria infections but is rarely fatal.
All four species of Plasmodium have been found in the endemic counties of the Pacific, although data on their relative frequency are patchy (Black 1955). Data from the Global Health Atlas of the World Health Organization (WHO) indicate that over the past five years for which figures are available (1999–2003) P. falciparum infection has hovered at around 80% of reported cases in Papua New Guinea, 70% in Solomon Islands and 50% in Vanuatu (Figure 1).
Insert Figure 1 about here
P. falciparum is justifiably regarded as the greater menace because of its association with high levels of human mortality, but there is a resurgence of interest in P. vivax because of the huge burden it places on the health, longevity and prosperity of human populations (Mendis et al 2001). It has been remarked that the true burden of P. vivax malaria has been grossly underappreciated and, globally, is probably in the region of a quarter of a billion clinical cases a year (Price et al 2007).
Mosquito vectors
Of the 3,000 known species of mosquito, only 30–40 are implicated in the transmission of the Plasmodium parasite to humans, all of them in the Anopheles genus (Norris 2004). One mosquito species, An. gambiae, has particular notoriety because it is a highly efficient disease vector due to its longevity, density and liking for human hosts (Hay et al 2004).
Each species of mosquito has a characteristic pattern of diel activity, but in all species it is the adult female alone who feeds on blood, using the protein-rich haemoglobin to nourish her eggs. Once a female has taken a blood meal she rests for a few days while the blood is digested and the eggs are developed. After laying her eggs, the female resumes host-seeking, until she comes to the end of her life, usually one or two weeks later.
Not much was known about the distribution of particular species of mosquito in the Pacific until the Second World War. However, the enormous impact of malaria on foreign troops prompted numerous vector studies by Australians and Americans (Joy 1999). Their finding that An. farauti was the most common malaria vector in the region (Black 1955) was confirmed by classification work that followed in the 1950s and 1960s (Iyengar 1955; Belkin 1962). An. Farauti characteristically breeds in semi-permanent waters such as swamps, ponds and lagoons, and to a lesser extent in temporary collections of water such as puddles and pools (Service 2004).
Human hosts
Malaria has an ancient origin and has probably been with humans since before we were human (Finkel 2007). Parasite and host are thus well adapted to each other. Indeed, malaria is claimed to be the strongest selective pressure on the human genome in recent history because of its high mortality and morbidity (Kwiatkowski 2005). In areas where malaria is endemic, populations display a variety of genetic mutations that confer a selective advantage by giving a degree of resistance to the Plasmodium parasite. The sickle cell trait, α– and β–thalassaemias, and Duffy antigens are some of the mutations that confer resistance.
These genetic adaptations are found in relevant Pacific populations. The α-thalassemia mutation is found in Vanuatu in a distinct north-south gradient that reflects the level of malaria endemicity. The highest frequencies of the mutation are found in the north where malaria, and malaria selection, is most intense (Lum 2007). Additionally, many Austronesian-speaking peoples have a genetic mutation that protects them, not from malaria, but from hyperreactive malarious splenomegaly, which is an often fatal affliction found among populations chronically exposed to malaria (Kelly 2000). These and other studies provide valuable examples of the role of genetics as a determinant of malarial health in the Pacific (Kimura et al 2003).
Transmission dynamics
The dynamics of malaria transmission are exceedingly complex because they involve attributes of, and interactions between, vectors, hosts and parasites (Foster and Walker 2002). Yet, understanding the steps in the transmission cycle can help evolutionary biologists to identify malaria control strategies by targeting vulnerable points in the cycle (Paul et al 2003). Key variables relating to the vector are: the species of mosquito, innate preference for different human or animal hosts, longevity, frequency of blood feeding, speed of reproduction, capacity to acquire and transmit the parasite, and resistance to insecticides. Some key variables relating to the host are: their natural (genetic) immunity to the parasite, immunity acquired by surviving exposure, population density, age and health status, and social behaviours. The key variables relating to the parasite are the species and strain, and their resistance to anti-malarial drugs. Overlaid across this matrix are environmental considerations such as climate (temperature, rainfall, humidity), availability of mosquito breeding and resting sites, and the existence of vector competitors (Ault 1989).
A number of these factors are utilised in the concept of vectorial capacity, which was developed by Garrett-Jones (1964) as a quantitative measure of the potential for a mosquito to transmit disease-causing parasites at a specific geographic location. Vectorial capacity can be seen as the product of three components: (i) the chance that a female vector will acquire the parasite from an infected host; (ii) the period that the vector can be expected to live in an infective state; and (iii) the number of bites inflicted on a host each day by an infected female vector. Each component is itself influenced by other factors, some relating to inherent properties of the mosquito vector (e.g. feeding frequency) and others to the interaction between the vector and host (e.g. vector density). Although vectorial capacity does not purport to model all aspects of malarial transmission, it has proved to be a useful tool for conceptualising ‘how the ecological components of the transmission cycle of many vector-borne parasites interact’ (Reisen 2002).
The distribution of malaria
Malaria thrives in hot climates because the Plasmodium parasite matures more quickly in the mosquitoes that carry it, making transmission more effective. The disease is thus predominantly found in tropical and sub-tropical regions. It is currently endemic to 109 countries (WHO 2008).
Human efforts to control malaria have restricted its distribution over time. Between 1900 and 2002 the geographic area of human malaria risk was reduced by about half, from 53% to 27% of the Earth’s land surface (Hay et al 2004). This reduction has not been evenly distributed. Far more progress has been made in controlling malaria in the higher latitudes where endemicity is low and lower temperatures limit parasite reproduction (Sachs and Malaney 2002).
Despite the decline in the geographic area of malaria risk, the human populations at risk have increased from 0.9 billion in 1900 (77% of world population) to 3.3 billion in 2006 (50% of world population). This is a product of world population growth in the 20th century, underpinning the claim that ‘human demographics continually shift public-health goalposts’ (Hay et al 2004:334). The distribution of malaria risk and burden varies greatly by region (Table 1). In Africa, 84% of the population is at some risk of contracting malaria, but this is true of only 50% of the population in the Western Pacific, and 15% in the Americas (WHO 2008). Similarly, there are substantial variations in the contribution of each region to the number of clinical malaria cases and estimated malaria deaths. However, the regional data do not give a good picture of malaria risk in the Pacific because WHO’s Western Pacific administrative region comprises 37 countries and its aggregated data are heavily dominated by the populations of China, Japan, Korea, Philippines, Malaysia and Vietnam. Measured against the combined population of these six countries alone (1,698 million in 2007), the population of Papua New Guinea, Solomon Islands and Vanuatu (7 million in 2007) is invisible.
Insert Table 1 about here
Information about the spatial distribution of malaria gives only a partial understanding of a disease whose transmission dynamics depend on the level of endemicity, which in turn affects the age of first exposure, the development of host immunity, and the expected clinical spectrum of disease (Hay and Snow 2006). Until recently, the only global map of malaria endemicity dated from a study completed by Lysenko and Semashko (1968) over 40 years ago. This informational deficit is now being addressed through the work of the Malaria Atlas Project, whose goal is to develop the science of malaria cartography by collecting and analysing global survey data on malaria endemicity (Hay and Snow 2006). The spatial data will be released into the public domain periodically. As at 7 March 2009, the project held 13,621 geo-positioned surveys from 84 countries, including 263 records from Papua New Guinea and 81 from Vanuatu, but only six from Solomon Islands (Malaria Atlas Project 2009). In 2008 the Project released the first contemporary data and maps of the geographical limits of P. falciparum malaria risk. These are based on reported annual parasite incidence (API) in combination with temperature and aridity data, which affect the likelihood of malaria transmission (Figure 2). The study shows that 2.37 billion people (about 35% of the world’s population) live in areas at some risk of P. falciparum transmission, including 4.11 million in Papua New Guinea, 0.43 million in Solomon Islands, and 0.22 million in Vanuatu. However, a sizeable portion of the global population—nearly one billion people—lives in areas of unstable malaria transmission, where elimination of malaria is epidemiologically feasible. An equivalent map of the distribution of P. vivax malaria has yet to be produced because ‘less information is available and its biology is more complex’ (Guerra et al 2008).
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The geographic distribution of malaria in the Pacific is closely allied to the distribution of the Anopheles vector that transmits the parasite. It has been remarked that ‘Mosquitoes are an excellent illustration of the general rule that the fauna of the Pacific spreads out from the west towards the east. The farther one goes towards the east, the thinner is the fauna’ (Iyengar 1955:1). The pioneering work of Buxton and Hopkins (1927) led to the development of the ‘Buxton line’, which passes through southern Vanuatu and forms the eastern limit of the Anopheles mosquito in the Pacific.
It is now a widely remarked but little understood fact that malaria appears to have met an ecological barrier in the south-west Pacific at 1700E Longitude and 200S Latitude. To the west of the line, in Melanesia, malaria constitutes a major public health problem; to the east, Polynesia remains essentially malaria free (Hercus 1948–49). The current geographic limits of malaria in the Pacific, taken from Miles (1997), are shown in Figure 3. Elsewhere in the Pacific, the presence of mosquito vectors other than Anopheles has long generated public health risks for vector-borne diseases such as dengue, and continues to do so (Kuno 2007).
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While malaria in the Pacific is seen most frequently in countries west of the Buxton line, cases have been reported in other Pacific Island countries, such as Fiji and Tonga (Ram and Malani 1978; Finau 1979). These cases of ‘imported malaria’ are of two types: individuals with histories of malarial infection in endemic countries, who then suffer relapses outside those countries; and travellers who are infected shortly before leaving an endemic area and manifest a primary infection after arrival at their destination. The latter situation poses difficulties for the diagnosis of malaria because ‘the doctor is not thinking of it’ and because the disease commonly presents in an early non-specific form (Finau 1979: 465).

Measuring malaria in Pacific populations
It is hard to assess accurately how much malaria there is the Pacific. Difficulties arise because of uncertainty in clinical diagnoses, the variety of measures used to indicate incidence and prevalence, and the inaccuracy of malaria data based on passively reported national records.
Difficulties of accurate diagnosis
The correct diagnosis of malaria is important for clinical and epidemiological purposes. Clinically, prompt and accurate diagnosis is vital in selecting an appropriate drug intervention for a disease that can be rapidly fatal. Epidemiologically, accurate diagnosis is necessary for the effective design, implementation and evaluation of health interventions (Young 2005).
WHO treatment guidelines suggest that malaria diagnosis should be based on both clinical criteria (signs and symptoms) and parasitological criteria (detection of parasites in the blood) (WHO 2006). Diagnosis on the basis of clinical criteria alone can lead to error because the first symptoms of malaria are non-specific and similar to the symptoms of many minor viral illnesses: headache, muscle ache, fatigue, fever and chills.
Microscopic examination of blood samples is the most reliable method of diagnosis but it is not available in many developing countries (Price et al 2007), or in remote highland or island locations in the Pacific. In Papua New Guinea, for example, there were 84,051 laboratory-confirmed malaria cases in 2006, but 20 times as many clinically diagnosed cases (1,676,681) (WHO 2008: Annex 2, 3). The accuracy of these clinical diagnoses is unknown. While the use of rapid diagnostic tests (RDTs) may offer a partial solution, these tests suffer from their own drawbacks of higher cost, variable sensitivity and specificity, and vulnerability to heat and humidity (WHO 2006).
Measures of incidence and prevalence
The measurement of malarial transmission is a science unto itself (Hay and Snow 2006). One common method is to determine the parasite rate (PR). This cross-sectional measure of prevalence is the proportion of a sample population (usually the 2–10 year age cohort) that is confirmed positive for malaria by identifying the parasite in blood slides. Another measure is the entomological inoculation rate (EIR), which involves estimating the number of infectious mosquitoes and the average number of bites per person per year (Smith 2005). Other measures of transmission include vectorial capacity, basic reproduction number, and serological markers.
These sophisticated tools are often used in small-scale studies but they are not well suited to the task of planning health interventions on a national or global scale, as can be seen from the work undertaken to measure attainment of the United Nations Millennium Development Goals (MDG). One of the health-related targets under the MDG is to halt and begin to reverse the incidence of malaria by 2015. For this purpose WHO uses two measures: malaria ‘prevalence’ (the number of notified malaria cases per 100,000 population per year); and death rates (malaria-specific mortality of children under five years of age per 1000 live births per year) (WHO 2003).
Pacific data
The data on malaria in Melanesia collected by WHO are limited. Like much WHO disease data, they are based on passively reported national records. This method of data collection misstates the burden of disease for several reasons: some malaria patients do not seek treatment at all, or use private health facilities; not all cases presented to public health facilities are reported by them; and a portion of clinically diagnosed cases do not have malaria (WHO 2008). In the African context, the relatively few patients who have contact with health services have been aptly described as ‘the ears of the hippopotamus’ (Breman 2001:1). Alternative estimation methods suggest that the actual number of P. falciparum cases outside Africa is up to three times the WHO estimates (Snow et al 2005). WHO now recognizes this problem and calculates that in 2006 only 37% of estimated malaria cases worldwide were reported. The discrepancy is much smaller in the Western Pacific region, where reported cases are thought to account for 95% of estimates (WHO 2008), but the situation in Melanesia is not specifically identified.
With this qualification, Figure 4 shows the absolute number of reported malaria cases in three endemic countries in Melanesia from 1990–2006 in logarithmic scale. Three notable trends are the relatively stable number of reported cases in Solomon Islands; the rise and subsequent fall in the number of reported cases in Vanuatu since 1999; and the erratic figures for Papua New Guinea, which may be a reflection of real-world events or an artifact of malaria reporting. For example, the dip in reported cases in Papua New Guinea in 1997–1999 may have been due to a prolonged drought, which reduced mosquito numbers, as well as incomplete reporting of malaria cases as a result of the closure of many health centres during the drought. Similarly, the 20-fold increase in reported cases from 2000–2001 may reflect changed reporting practices, from recording confirmed cases only to recording confirmed and probable cases.
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These absolute figures give an indication of the scale of human affliction but they do not take account of the population at risk. Figure 5 shows the number of confirmed malaria cases per 1,000 population per year from 1990–2007. This rate is better seen as a measure of incidence rather than prevalence, although the episodic nature of malaria may blur the distinction. The chart shows a marked fall in malaria incidence in all three countries in the early 1990s; a temporary but significant rise in incidence in Solomon Islands and Vanuatu from 1999–2003; a relatively low and stable incidence in Papua New Guinea in recent years; and an incidence in Solomon Islands that is still many times higher than that of its neighbours. In the early 1990s Solomon Islands had the unenviable distinction of having one of the world’s worst malaria rates (Keith-Reid 1983), but some progress has been made since then. Even so, in 2003, Solomon Islands ranked tenth in the world for malaria incidence, but ranked first in the world outside Africa (WHO 2005).
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Figure 6 shows the malaria-specific mortality rates for three Melanesian countries over the period 1997–2007. The average rate for Papua New Guinea was 10.6 deaths per 100,000 population, with no discernable time trend. The average rate for Solomon Islands was 8.4 deaths per 100,000 population, with a sustained increase in the mortality rate (peaking at 14.9 in 2003), followed by a pronounced decline. The spike in the mortality rate in Solomon Islands between 2000–2003 is most likely due to the breakdown in health service delivery during a period of civil unrest (‘The Tensions’), while the higher average mortality rate in Papua New Guinea may reflect the higher proportion of P. falciparum malaria in that country compared with Solomon Islands (see Figure 1).
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Socio-economic costs of malaria
The global burden of malaria
The cost of malaria is vast in human, social and economic terms. According to WHO, in 2006 around 3.3 billion people lived in areas at some risk of malaria transmission; there were an estimated 247 million cases of the disease; and 881,000 people died from it (WHO 2008). Children and pregnant women are the most vulnerable populations; one child dies from the disease every 40 seconds. Malaria is also a major cause of anaemia, low birth weight, premature birth and infant mortality.
The burden of malaria can be gauged from data produced by the Global Burden of Disease project. In 2002, malaria ranked as the 9th leading cause of death globally, accounting for 2.2% (1.27 million) of the 57 million deaths that year. The Global Burden of Disease framework utilises a metric (disability-adjusted lost years—DALYs) that measures the years of healthy life lost due to death or disability. Using this summary measure, malaria ranked 8th in 2002 as a leading cause of disease burden, accounting for 46 million DALYs, or 3.3% of the global total. Of those 46 million DALYs, 11% were healthy years lost due to disability, with the balance being years lost due to premature death (WHO 2002; Mathers et al 2007). These estimates will be updated in 2010 under a new study led by an international consortium of institutions whose goal is to produce comprehensive and comparable estimates of the global burden of diseases, injuries and risk factors (Global Burden of Disease Study 2008).
The cost of malaria is not only large but extremely inequitable. Malaria is a ‘plague of the poor’ (Finkel 2007:41), with most of the cost being borne by the poorest regions of sub-Saharan Africa, where 80–90% of global malaria deaths occur. When examined according to WHO’s six administrative regions, Africa accounted for 91% of global mortality from malaria in 2006 (Table 1). Against this, the contribution of the Western Pacific seems small (<1% of global mortality). But the sheer scale of the African problem masks the human cost of malaria even within the Western Pacific, where there were an estimated 4,021 malaria deaths in 2006, while another 1.76 million people were affected by the disease (WHO 2008).
Economic costs
It has been remarked that ‘as a rule of thumb, where malaria prospers most, human societies have prospered least’ (Sachs and Malaney 2002:681). In 1995 the gross domestic product (GDP) of malarious countries was one-fifth that of other countries, while their rates of economic growth were nearly 2% per year lower than other countries. One explanation of this association is that poverty causes malaria, and there is some evidence for this. The converse explanation is that malaria causes poverty, for which there is compelling evidence (Gallup and Sachs 2001).
A starting point for determining the economic costs of malaria is the immediate medical costs of the disease, including private and public expenditures on prevention, diagnosis and treatment. One study found these costs to amount to 1% of a country’s GDP (Sachs and Malaney 2002). Another cost is demographic. Mortality from malaria is concentrated among children under five years of age. These deaths lead to the loss of economic value of resources invested in the children who do not survive, as well as distort the reproductive decisions of their parents (Sachs and Malaney 2002).
A further significant cost is that malaria depresses the rate of human capital accumulation and thus lowers economic growth. An illustration is the effect of malaria on absenteeism of school age children. A study in Solomon Islands found that each case of malaria in a school age child resulted in an average of 5.3 days absenteeism, which was quantified as a lost annual investment in education equivalent to 27 primary school teachers (Kere et al 1993). The experience in the classroom is echoed in the workplace, where the absence of workers is often combined with low productivity of attending workers due to malaria-induced anaemia.
Malaria also suppresses linkages between malarious and non-malarious regions, which may curb foreign investment and tourism in endemic areas (Sachs and Malaney 2002). The construction of the Panama Canal is an apposite historical example. The French commenced this massive infrastructure project in 1880, when the role of mosquitoes in transmitting malaria was poorly understood. The project was abandoned in 1889 after 22,000 workers had died from malaria and other vector-borne diseases. The project lay idle for 15 years until the Americans took up the task of completing the canal in 1904, once strategies had been developed to control yellow fever and malaria in the canal zone (Spielman and D’Antonio 2001; Sutter 2007). Endemic countries may also find it difficult to promote tourism because international travellers find malarious destinations less attractive, which has been the experience in Solomon Islands (Baselala 2007).
Social and cultural context
The economic burden of malaria has been frequently studied and is generally well described but the social burden of the disease remains elusive (Jones and Williams 2004). While Western medicine is premised on ‘universal scientific truths’ that can be observed, measured and quantified, the experience of ‘illness’ is a subjective one, influenced by culture, values and beliefs. These are important considerations in Papua New Guinea, Solomon Islands and Vanuatu, which are predominantly traditional rural societies, with low rates of urbanisation and widely-held custom beliefs and practices. Local perceptions about disease causation and treatment may not conform to biomedical notions, and socioeconomic status may play a significant role in the distribution of the burden of disease.
For example, in parts of Africa where malaria is highly endemic, uncomplicated malaria may be seen as a mild, everyday illness. Normalisation of the disease may place responsibility for treatment on the individual or close family, and there is low social pressure to seek medical intervention. Even in cases of severe malaria, the ability to access health services is overlaid by considerations of gender, disparate roles as caregiver or breadwinner, one’s position in the social hierarchy, and the intercession of traditional healers (Jones and Williams 2004). These anthropological considerations are specific to particular cultures and cannot be extrapolated from Africa to the Pacific. Nevertheless, they suggest that the social burden of malaria can be fully understood only if grounded in an understanding of traditional cultures, values and beliefs in Melanesian societies.

Health interventions
The impact of malaria on the health of human populations has evoked a succession of health interventions to ameliorate the disease. These have come in waves as scientific understanding of the relationship between parasite, vector and host has matured. It is now broadly accepted that malaria control requires an integrated approach and that the optimal mix of interventions depends, among other things, on the intensity of malaria transmission (Hay and Snow 2006). Several interventions have been of particular relevance to the Pacific.
Environmental control of mosquito habitats
All mosquitoes share a pattern of biological development that is linked to aquatic breeding sites. Anything that can hold water can provide a habitat for mosquitoes (Norris 2004). Once the role of Anopheles mosquitoes in the transmission of malaria had been discovered, the way was clear to introduce environmental controls over mosquito breeding sites by clearing swamps and improving drainage. This represented the first significant effort to control malaria in the 20th century (Hay et al 2004).
One colourful illustration of this approach in Vanuatu (then New Hebrides) was the enactment of a regulation by the joint British and French administration in 1942. The Malaria (Control) Act requires every person occupying cultivated land to take all necessary measures to prevent any coconut shell capable of holding rain water being used as a breeding place for mosquitoes. Breach of the prohibition attracts a penalty of imprisonment but—anticipating the difficulty of enforcing such a law in a land of coconut palms—no offence is committed unless the coconut shells are found in sufficient number to establish the bad faith or negligence of the occupier.
Residual insecticide spraying: the era of DDT
A second wave of intervention followed the discovery in 1939 of the insecticidal properties of dichloro-diphenyl-trichloroethane (DDT). The pesticide was cheap to produce and had valuable residual properties: microscopic amounts sprayed in dwellings could kill mosquitoes for months afterwards. Seizing this new opportunity, WHO implemented the Global Malaria Eradication Program from 1955–1969. There were many early successes: nearly all the shrinkage in the spatial distribution of malaria in the 20th century was achieved in this period (Hay et al 2004). Malaria was virtually wiped out in many parts of Melanesia, where spraying with DDT continued practices that had commenced in some places during the Second World War (Black 1955; Avery 1974).
The tide turned with the publication of Rachel Carson’s influential book, Silent Spring, which gave a damning account of the indiscriminate use of DDT in United States agriculture, and its effects on the environment, wildlife and humans (Carson 1962). DDT was subsequently banned in the United States and elsewhere for agricultural purposes. Although its use for vector control was still permitted, it became difficult to procure (Finkel 2007; Pearce 2007).
In the Pacific, the demise of DDT in the 1980s was hastened by other factors. Solomon Islanders did not readily accept spraying in their homes, and the administrative and logistical support necessary to conduct controlled spraying was lost after independence in 1978 (Keith-Reid 1983). Nevertheless, DDT residual house spraying remains an effective health intervention in endemic areas (Over et al 2004) and the practice has continued in some Melanesian countries. In 2004–2006, residual spraying covered over 46,000 households in Solomon Islands and 2,000 households in Papua New Guinea, but none at all in Vanuatu (WHO 2008).
Drug prophylaxis and treatment
Traditional knowledge and modern medicine have both contributed to the prevention and treatment of malaria through the use of drugs. The first widely known remedy was discovered in South America in the 17th century, where the bark of the cinchona tree (known locally as ‘quina quina’) provided a remedy. Later distributed as ‘quinine’, it was effective in disrupting the reproduction of the parasites, but it was short-acting and difficult to source (Finkel 2007).
In the 1940s a synthetic medicine, chloroquine, was discovered to have similar properties to quinine, and was inexpensive, safe and long-lasting. However, resistant strains of Plasmodium emerged because genetic mutations gave some parasites a selective advantage with respect to the drug. Chloroquine-resistant P. falciparum has been documented since the 1950s, but resistant strains of P. vivax have been slower to emerge. In the Pacific, chloroquine-resistant P. vivax malaria was first documented in Papua New Guinea in 1989, and spread soon after to Solomon Islands and Vanuatu (Price et al 2007). The limitations on the effectiveness of chloroquine has encouraged the development of other anti-malarial drugs (such as primaquine) and these are used widely throughout Melanesia, but a degree of resistance has now arisen to all classes of anti-malarials, save one (WHO 2006). Prophylaxis is also available through use of tetracycline antibiotics, which are effective in killing parasites in the blood but are unsuitable for long-term use.
The new hope is based on a traditional Chinese medicine derived from the Artemesia plant, which has led to a new generation of pharmaceuticals known as artemisinin. Typically the drug is mixed with other anti-malarial compounds (with independent modes of action against the parasite) to reduce the risk of new drug resistance developing. Artemisinin-based Combination Therapy (ACT) is now the first line of treatment for P. falciparum malaria (WHO 2006) although its high cost often necessitates use of ineffective drugs in the poorest countries (Attaran et al 2004).
Insecticide treated nets
The idea of using bed netting to protect people from the night-feeding habits of many species of mosquito is not new. Traditionally, South Pacific Islanders have used sheets of tapa—a fine cloth made from the inner bark of the mulberry, breadfruit or banyan tree—as mosquito netting, in addition to its uses for clothing, ceremonial and ritual purposes (Neich and Pendergrast 2001).
Mosquito nets act as a physical barrier between vector and host, but their effectiveness is significantly enhanced when a chemical barrier is added to the physical one by treating the net with pyrethroid insecticides. The insecticide kills mosquitoes that come into contact with it, thereby reducing the vector population for the benefit of the whole community, not just those who sleep under the nets. The impregnation of nets with long-lasting insecticide that survives multiple washes gives an even higher level of protection (WHO–GMP 2007).
The use of insecticide treated nets (ITNs) is effective in reducing the disease burden of malaria. A study in sub-Saharan Africa concluded that ITNs reduced all-cause child mortality by 18% and reduced clinical episodes of malaria by 50%. A study in Solomon Islands confirms, but does not quantify, these health benefits (Over et al 2004). ITNs are not only effective, but cost effective. It is on this basis that they have been recommended in preference to residual spraying in Solomon Islands (Kere and Kere 1992), but in practice they have been used in combination with other methods of mosquito control. Of the population at risk of malaria in Melanesian countries in 2006, ITNs were available to 22% of people in Papua New Guinea, 25% in Solomon Islands, and 29% in Vanuatu (WHO 2008).
The importance of ITNs as a key health intervention is recognised under the United Nations Millennium Development Goals. WHO uses ‘percentage of population under five years of age in malaria-risk areas using insecticide-treated nets’ as a measure of effectiveness in preventing malaria. The recent experience in Melanesian countries represents significant progress towards this Millennium Development Goal but still falls well short of the target of full coverage for all people at risk, using only long-lasting ITNs (WHO-GMP 2007).

Biting back: charting a new course for the Pacific
Over 50 years ago, at the start of WHO’s Global Malaria Eradication Program, it was claimed that one can ‘be confident that malaria is well on its way towards oblivion’ (Russell 1955: viii). This mood of high optimism was misplaced. Malaria is no longer in retreat. With rapidly growing populations in areas of high endemicity, the number of malaria cases in Africa is estimated to double in the 20 years from 2000 to 2020 in the absence of effective interventions (Breman 2001). There is a similar concern in the Pacific. The combined population of Papua New Guinea, Solomon Islands and Vanuatu is expected to grow from 7.23 million in 2008 to 11.32 million by 2030—an increase of over 4 million people (56%) in 22 years (SPC 2008). This is due largely to continuing high rates of fertility (the total fertility rate in each country is 4.6, 4.7 and 4.4 respectively), which places ever greater numbers of children at risk of malaria. These are sobering thoughts, but recent developments provide grounds for cautious optimism. Steps have been taken towards developing a malaria vaccine, and there has been ‘heretofore unheard of political, strategic, and financial support for malaria scientific studies and control actions’ (Breman et al 2004:1).
A malaria vaccine
Childhood immunisation against communicable diseases has been one of the greatest public health successes of the past century, eradicating some medical conditions such as smallpox and polio, and effectively controlling many others (Centers for Disease Control and Prevention 1999). Encouraged by these successes, there have been intensive efforts to develop a vaccine for malaria at different stages of the parasite’s life cycle in the human host. The task is scientifically challenging. All existing vaccines target relatively simple organisms such as viruses and bacteria: a vaccine has never been developed against a complex parasite. Even so, there have been promising indications including, quite recently, GlaxoSmithKline’s investigational RTS,S/ AS01E malaria vaccine for infants (Aponte et al 2007; Bejon et al 2008). That vaccine reduced malaria infection in children aged 5–17 months by 53% in comparison with a control group when trialed in Kenya and Tanzania in 2007–2008. Several candidate vaccines are being investigated through the Malaria Vaccine Initiative (MVI), whose goal is to accelerate the development of malaria vaccines through partnerships with research organisations and pharmaceutical companies around the world. It is too early to be confident of success but, if the goal is achieved, a vaccine will give Pacific populations cost-effective and long-lasting protection against malaria.
Renewed international interest
Within the past ten years many international initiatives have placed malaria high on their list of health priorities. These initiatives include: the Roll Back Malaria partnership (1998); the United Nations Millennium Development Goals (2000); the Global Health Program of the Bill & Melinda Gates Foundation (2000); the Global Fund to Fight AIDS, Tuberculosis and Malaria (2002); the World Bank Booster Program for Malaria Control in Africa (2005); the U.S. President’s Malaria Initiative (2005); and the Global Malaria Program established within WHO (Breman et al 2004).
These initiatives share a number of important attributes: they provide institutional support for malaria research and action; they raise the profile of malaria in the eyes of stakeholders; and they harness public and private funding. The latter issue is critical. In 2001, WHO’s Commission for Macroeconomics and Health estimated that effective malaria prevention and treatment would require an additional US$2,500 million per year by 2007, rising to US$4,000 million per year by 2015 (WHO–CMH 2001). In 2003 the total amount of international aid dedicated to malaria control was dramatically less than this (Narasimhan and Attaran 2003), but the rush of new actors now appears to be moving the international community in the right direction.
Pacific regional capacity
Pacific Island countries have been direct beneficiaries of these international programs. For example, the Global Fund awarded US$20.1 million in 2004, and a further US$70.1 million in 2008, for malaria prevention and control in Papua New Guinea. The Global Fund also awarded US$7.6 million for similar purposes in Solomon Islands and Vanuatu through a multi-country malaria program in 2003 and 2005.
While international funding is essential, regional organisations and initiatives are important vehicles for combating malaria. These vehicles potentially include the Pacific Islands Forum Secretariat (PIFS) and its Pacific Plan; the Secretariat of the Pacific Community (SPC) and its Public Health Program; the Council of Regional Organisations in the Pacific (CROP) and its Health and Population Working Group; the Fiji School of Medicine (FSM) and its Department of Public Health; and the biennial meeting of regional health ministers.
SPC has taken the lead in coordinating the malaria control programs in Solomon Islands and Vanuatu under the Global Fund grants. However, in view of the importance of malaria to public health in Melanesia, it is surprising that other regional bodies have not been more active in addressing the disease. This might be because malaria is not endemic in the majority of constituent countries, or because regional work on communicable diseases is currently focused on other priorities such as HIV/AIDS and dengue (Lepers 2007). The institutions that are needed for increased regional focus on malaria exist, and some regional donors have recognised the need for further action. In May 2007 the Australian Government announced funding of AUD$25 million over four years for the Pacific Malaria Initiative. The program aims to train medical staff in malaria prevention and detection; improve the recording and tracking of malaria incidence; and support malaria education programs in remote regions.

The challenges ahead
The Millennium Development Goal of halting and beginning to reverse the incidence of malaria by 2015 is an ambitious yet achievable goal for the Pacific, but the realisation of that goal is threatened by a number of considerations.
Cross-border movement of vectors and hosts
One enduring concern is that malaria will take root in non-endemic Pacific Island countries, thus placing new populations at risk of the disease. This may occur in two ways. The first possibility is that infected vectors (as adults, eggs, larvae or pupae) may be transported across borders through air and shipping routes to colonise new environments and infect new populations of human hosts. Biological invasions by vectors—characterised by arrival, establishment and spread—have been well-documented for some mosquito species (Lounibos 2002). In 1930, the mosquito An. gambiae was inadvertently transported by aircraft or steamship from West Africa to Brazil, carrying the P. falciparum malaria pathogen with it. Well-suited to the climatic conditions of its destination, An. gambiae spread widely in north-east Brazil, leading to malaria epidemics that cost 16,000 lives (Tatem et al 2006a).
A less dramatic example of the same phenomenon is ‘airport malaria’, namely, malaria that is found in and near airport hubs among persons who have not travelled to countries where malaria is endemic (Gratz et al 2000; Martens and Hall 2000). Airport malaria occurs when infected vectors are transported by airplane, released at the destination, establish themselves in the vicinity of the airport, and then give rise to local malaria transmission. Scientists who have modeled the spread of malaria through global transport networks have found that the pattern and risk of airport malaria can be substantially explained by the volume of air traffic and the similarity between the climate of the origin and destination (Tatem et al 2006b). The risk of malaria spreading beyond the vicinity of an airport depends upon of a range of factors such as the availability of suitable mosquito habitats, competition from local mosquitoes, and the distribution of human populations. The danger of airport malaria is not unique to the Pacific, but nor is the region immune from these concerns. Both Hawaii and Guam have a substantial number of non-indigenous mosquito species, which are thought to have arrived from abroad via sea transport or inter-island air transport (Lounibos 2002). Pacific Island countries appear to be especially vulnerable to vector migration because communication between widely dispersed islands is principally by air, and their climates and ecologies are similar. A species established on one island might thus readily establish itself on another (Gratz et al 2000).
While concerns about the migration of malaria vectors across borders pre-date the advent of air travel, rapid high-volume air cargo and passenger flights have given the matter poignancy. The United Nations World Tourism Organization has forecast that international passenger arrivals in the ‘East Asia and Pacific region’ will grow at an average annual rate of 6.5% from 1995 to 2020, bringing the number of annual arrivals from 81 million to 397 million (UNWTO 2000). The contribution of the Pacific to this total is not specified but if a similar trend applies the high growth rate will reinforce the dangers inherent in the movement of vectors across borders, and underpin the need for stringent disinsection of aircraft and other modes of transport.
A second source of malaria risk in non-endemic Pacific Island countries is the cross-border movement of infected human hosts, which can create problems at the individual and population levels. For individuals who have been infected with the malaria parasite shortly before travelling, there can be problems in diagnosing the condition after arrival because early symptoms of malaria are often non-specific, and physicians in non-endemic countries may not be attuned to the possibility of this diagnosis (Finau 1979). For populations, there is the risk that local vectors may acquire the parasite from infected human hosts and thereby trigger a disease outbreak in the population if local conditions are favourable (Tatem et al 2006a).
Resistance to anti-malarial drugs
A further concern of global significance is the capacity of Plasmodium parasites to develop resistance to pharmaceuticals that have been invented to kill them. Spontaneously occurring genetic mutations give some parasites a greater chance of surviving a dose of a drug than parasites without the mutation. Over time, the pressure of natural selection allows drug-resistant strains to survive and thrive. This has occurred in each major class of anti-malarial drug other than artemisinin—a testament to the sheer reproductive force of an indescribable number of parasites and their mosquito vectors. Moreover, the geographical reach of drug-resistant Plasmodium parasites has continued to grow due to the international movement of vectors and hosts along routes of trade and tourism (Tatem et al 2006a). The compromising of once first-line drug interventions has imposed significant costs on the health of populations at risk: even the less virulent P. vivax parasite is now associated with severe and fatal malaria in young children in some places (Tjitra et al 2008).
There is a justifiable apprehension that Plasmodium will also develop resistance to the newest weapon in the arsenal. To minimise this risk, artemisinin is being administered in combination therapies; efforts are being made to reduce the indiscriminate use of anti-malarials; and greater attention is being paid to the manner in which drug-resistance spreads from areas of low endemicity to areas of high endemicity (Hay et al 2004).
Environmental and climatic changes
Mosquitoes and parasites are sensitive to environmental and climatic conditions, and the transmission of malaria is correspondingly affected by changes in these conditions. Economic development is often associated with land use changes that may exacerbate mosquito-borne diseases by expanding the vector’s existing habitats or creating new habitats (Norris 2004). The construction of ponds and dams increases the surface area available for vector breeding, while deforestation removes the canopy and creates new vector habitats. Land use changes that accompany the growth of urban areas and the expansion of agriculture may also place people in closer nexus with vector habitats, creating additional opportunities for disease transmission.
There is an emerging consensus that the world’s climate system is warming, as evidenced by increases in average air and ocean temperatures, widespread melting of snow and ice, and rising average sea level (Intergovernmental Panel on Climate Change 2007). Global warming may have long-term effects on the transmission of malaria by altering variables such as temperature, humidity, rainfall and seasonality (Reiter 2001; McMichael et al 2006; Gage et al 2008), allowing mosquitoes to ‘colonize higher altitudes and farther latitudes’ (Finkel 2007: 58). For example, malaria transmission does not generally occur at high altitudes (variously described as altitudes above 1600–2500m) because the lower temperatures interrupt the life cycle of the parasite in the mosquito (Bishop and Litch 2000). In Papua New Guinea, global warming may in time reduce the size of the cooler, malaria-free zones in the highlands (Barnett 2007). In recent times, malaria outbreaks have been documented in several tropical and sub-tropic highland zones around the world (Tibbetts 2007). Not all of these can be attributed to climate change, but the possibility of such change is a source of disquiet.

Conclusion
Most Pacific Island countries are located in the tropics, where there is an abundance of mosquitoes with the potential to carry vector-borne diseases. For reasons not fully understood, malaria is endemic in only three Melanesian countries west of the ‘Buxton line’—Papua New Guinea, Solomon Islands and Vanuatu. The burden of malaria within those countries is serious. Although the incidence of malaria has fallen modestly over the past four years, the longer history is erratic and the incidence of malaria in Solomon Islands persists at levels that are high by regional standards. The proportion of cases caused by the most virulent species of parasite, P. falciparum, is also high—ranging from 50% to 80% according to the country.
History shows that appropriate health interventions, used in combination, can make a significant difference to the burden of malaria in areas of low to moderate endemicity. The converse is also true: failure to take appropriate action can unleash a malaria epidemic. Solomon Islands went from a state of near eradication of malaria in 1976 to having one of the highest incidences in the world outside Africa, in just 15 years (Over et al 2004).
The sheer reproductive force of the Plasmodium parasite and the Anopheles mosquito, if left unchecked, is a major biological constraint on malaria control in the Pacific. In addition, malaria control has been compromised in the past by problems of geography (remote highlands, dispersed islands), civil unrest, and natural disasters such as the tsunami in Solomon Islands in 2007.
There is a need for prompt and concerted action on malaria at the national, regional and international levels. This need is self-evident in Melanesia, but other Pacific Island countries should not be complacent. The threat posed by the movement of disease vectors to new island habitats is amply demonstrated by the outbreaks of airport malaria near international airport hubs in Europe and America.
At the domestic level, endemic countries in the Pacific need to prioritise malaria control by extending the distribution of long-lasting insecticide treated nets and the application of indoor residual spraying to dwellings in the worst affected areas. At the regional level, the capacity of existing Pacific institutions needs to be harnessed through their acceptance of malaria as a pan-Pacific concern. At the international level, the opportunities presented by the ‘rush of new actors’ should be seized to enhance funding and logistical support for malaria programs tailored to Pacific needs. And running across all levels is the need for more community education about malaria in terms that reflect the traditional cultures, values and beliefs of those communities.
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Figure 1: P. falciparum and mixed cases as percentage of all reported malaria cases by country, 1990–2003

Source: World Health Organization, Global Health Atlas. www.who.int/globalatlas (accessed 23 January 2008).


Table 1: Distribution of malaria risk, cases, type and deaths by WHO region, 2006
WHO Region	Africa	Americas	Eastern Mediter-ranean	Europe	South-East Asia	Western Pacific	World
Proportion of population in each region at risk of malaria	84%	15%	55%	2%	77%	50%	50%
Contribution of each region to the global burden of estimated clinical malaria cases	86%	1%	3%	<1%	9%	<1%	100%
Proportion of clinical malaria cases in each region caused by P. falciparum	98%	29%	76%	2%	56%	67%	92%





Figure 2: Global distribution of P. falciparum malaria risk
(see separate file for soft copy of map)
 
Source: Guerra et al (2008). Areas were defined as stable transmission (dark-red areas, where PfAPI ≥ 0.1 per thousand pa); unstable transmission (pink areas, where PfAPI < 0.1 per thousand pa); or no risk (light grey). PfAPI is the annual parasite incidence of P. falciparum. Highland areas where risk was excluded due to temperature appear in light grey. This information was provided by the Malaria Atlas Project (MAP, http://www.map.ox.ac.uk), funded principally by the Wellcome Trust, U.K.


Figure 3: The Buxton Line and the Limits of Anopheles mosquitoes in the South Pacific

Source: Miles (1997:24). Reproduced with permission of the Otago University Press.


Figure 4: Reported malaria cases by country, 1990–2006

Source: WHO (2008), Annex 3a: Reported malaria cases 1990–2007.


Figure 5: Incidence of confirmed malaria per 1000 population by country, 1990–2007

Source: 1990–1996: WHO (2005) Annex 2; 1997–2007: World Health Organization, Western Pacific Regional Office, Malaria and other vectorborne and parasitic diseases, www.wpro.who.int/sites/mvp/data/ (accessed 12 March 2009).


Figure 6: Probable and confirmed malaria deaths per 100,000 population by country, 1997–2007

Source: World Health Organization, Western Pacific Regional Office, Malaria and other vectorborne and parasitic diseases, www.wpro.who.int/sites/mvp/data/ (accessed 12 March 2009). Limited data are available for Vanuatu.




